Back to results
US 12,590,133 B2Granted
IL-13/IL-4 superkines: immune cell targeting constructs and methods of use thereof
AssigneesThe Board of Trustees of the Leland Stanford Junior University, Medicenna Therapeutics Inc.
InventorsKenan Christopher Garcia, Ignacio Moraga Gonzalez, Fahar Merchant
Life of this patent
Estimating the term…
Abstract
Methods and compositions are provided for enhancing anti-tumor effector immune cells with a targeting construct comprising a human IL-13 superkine and/or a human IL-4 superkine. Cytokine or additional co-stimulatory sequences may also be included to enhance the tumoricidal effects of the cells.
Claims4
A composition comprising an immune cell targeting construct and an IL-2 or an IL-2 mutein, wherein the immune cell targeting construct comprises:
- an IL-13 superkine engineered to have increased affinity for interleukin 13 receptor α2 (IL-13Rα2), relative to native human IL-13 protein and decreased affinity for interleukin 13 receptor α1 (IL-13Rα1) relative to native human IL-13 protein and comprising at least one amino acid change relative to the wild-type IL-13 at one or more of positions selected from L10, R11, E12, I14, V18, R65, R86, D87, T88, K89, L101, K104, K105, F107, and R108, wherein the immune cell targeting construct targets a tumor and/or tumor microenvironment and/or targeting tumor antigens.
Dependencies are inferred from the claim text.